Cosmo Bio reports higher Q1 2026 net profit

5 articles · Updated · MarketWatch · May 8

The Japanese company posted net profit of Y222 million for the quarter ended 31 March, with revenue rising to Y3.33 billion from Y3.09 billion.
Operating profit slipped to Y271 million from Y273 million, while pretax profit fell to Y264 million from Y293 million.
Earnings per share increased to Y39.22 from Y37.22, and the results were prepared under Japanese accounting standards.

With revenue rising, why did Cosmo Bio's profits fall amidst Japan's booming biotech market?

How will breakthroughs in Alzheimer's research reshape the life sciences distribution industry?